|
[1]
|
Tornio, A. and Backman, J.T. (2018) Cytochrome P450 in Pharmacogenetics: An Update. Advances in Pharmacology, 83, 3-32. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Palrasu, M. and Siddavaram, N. (1969) Cytochrome P450 Structure, Function and Clinical Significance: A Review. Current Drug Targets, 19, 38-54.
|
|
[3]
|
Ma, Q. and Lu, A. (2007) CYP1A Induction and Human Risk Assessment: An Evolving Tale of in Vitro and in Vivo Studies. Drug Me-tabolism and Disposition, 35, 1009-1016. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Klomp, F., Wenzel, C., Drozdzik, M., et al. (2020) Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes. Pharmaceutics, 12, 1-25. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Zhang, Q.Y., Dunbar, D. and Kaminsky, L.S. (2003) Characterization of Mouse Small Intestinal Cytochrome P450 Expression. Drug Metabolism and Disposition, 31, 1346-1351. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Bogaards, J.J., Bertrand, M., Jackson, P., et al. (2000) Determining the Best Animal Model for Human Cytochrome P450 Activities: A Comparison of Mouse, Rat, Rabbit, Dog, Micropig, Monkey and Man. Xenobiotica, 30, 1131-1152. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Guo, J., Zhu, X., Badawy, S., et al. (2021) Metabolism and Mechanism of Human Cytochrome P450 Enzyme 1A2. Current Drug Metabolism, 22, 40-49. [Google Scholar] [CrossRef]
|
|
[8]
|
Hinson, J.A. (1983) Reactive Metabolites of Phenacetin and Acetaminophen: A Review. Environmental Health Perspectives, 49, 71-79. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Grzegorzewski, J., Bartsch, F., Kller, A., et al. (2021) Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing. Frontiers in Pharmacology, 12, Article ID: 752826. [Google Scholar] [CrossRef]
|
|
[10]
|
Faber, M.S., Jetter, A. and Fuhr, U. (2010) Assessment of CYP1A2 Activity in Clinical Practice: Why, How, and When. Basic Clini-cal Pharmacology Toxicology, 97, 125-134. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Lu, J., Shang, X., Zhong, W., et al. (2020) New Insights of CYP1A in Endogenous Metabolism: A Focus on Single Nucleotide Polymorphisms and Diseases. Acta Pharmaceutica Sinica B, 10, 91-104. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
胡云珍, 姚彤炜. 细胞色素P4501A的研究进展[J]. 中国药学杂志, 2003, 38(4): 246-250.
|
|
[13]
|
肖鹏, 周宏灏. 细胞色素氧化酶CYP1A2的研究进展[J]. 中南大学学报, 2008, 33(5): 456-460.
|
|
[14]
|
Doran, A.C., Burchett, W., Landers, C., et al. (2022) Defining the Selectivity of Chemical Inhibi-tors Used for Cytochrome P450 Reaction Phenotyping: Overcoming Selectivity Limitations with a Six-Parameter Inhibi-tion Curve-Fitting Approach. Drug Metabolism and Disposition, 50, 1259-1271. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Yamazoe, Y. and Yoshinari, K. (2019) Prediction of Regioselectivity and Preferred Order of Metabolisms on CYP1A2-Mediated Reactions Part 3: Difference in Substrate Specificity of Hu-man and Rodent CYP1A2 and the Refinement of Predicting System. Drug Metabolism Pharmacokinetics, 34, 217-232. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Liu, J., Sridhar, J. and Foroozesh, M. (2013) Cytochrome P450 Family 1 Inhibitors and Structure-Activity Relationships. Molecules, 18, 14470-14495. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Nguyen, V., Espiritu, M. and Elbarbry, F. (2020) Development and Validation of a Sensitive and Specific LC-MS/MS Cocktail Assay for CYP450 Enzymes: Application to Study the Effect of Catechin on Rat Hepatic CYP Activity. Biomedical Chromatography, 34, e4789. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Kawalek, J.C. and Andrews, A.W. (1980) The Effect of Solvents on Drug Metabolism in Vitro. Drug Metabolism and Disposition, 8, 380-384.
|
|
[19]
|
Hosono, H., Kumondai, M., Maekawa, M., et al. (2017) Functional Characterization of 34 CYP2A6 Allelic Variants by Assessment of Nicotine C-Oxidation and Coumarin 7-Hydroxylation Activities. Drug Metabolism and Disposition, 45, 279-285. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Bagdas, D., Muldoon, P.P., Zhu, A.Z., et al. (2014) Effects of Methoxsalen, a CYP2A5/6 Inhibitor, on Nicotine Dependence Behaviors in Mice. Neuropharmacology, 85, 67-72. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Zhang, W., Kilicarslan, T., Tyndale, R.F., et al. (2001) Evaluation of Methoxsalen, Tranylcypromine, and Tryptamine as Specific and Selective CYP2A6 Inhibitors in Vitro. Drug Metabolism and Disposition, 29, 897-902.
|
|
[22]
|
Martignoni, M., Groothuis, G.M. and de Kanter, R. (2006) Spe-cies Differences between Mouse, Rat, Dog, Monkey and Human CYP-Mediated Drug Metabolism, Inhibition and In-duction. Expert Opinion on Drug Metabolism Toxicology, 2, 875-894. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Juvonen, R.O., Kuusisto, M., Fohrgrup, C., et al. (2016) Inhibitory Effects and Oxidation of 6-Methylcoumarin, 7-Methylcoumarin and 7-Formylcoumarin via Human CYP2A6 and Its Mouse and Pig Orthologous Enzymes. Xenobiotica, 46, 14-24. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Li, L., Zhang, Q.Y. and Ding, X. (2018) A CYP2B6-Humanized Mouse Model and Its Potential Applications. Drug Metabolism Pharmacokinetics, 33, 2-8. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Klaassen, T., Jetter, A., Tomalik-Scharte, D., et al. (2008) As-sessment of Urinary Mephenytoin Metrics to Phenotype for CYP2C19 and CYP2B6 Activity. European Journal Clini-cal Pharmacology, 64, 387-398. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Mango, K., Kiss, A.F., Fekete, F., et al. (2022) CYP2B6 Allelic Variants and Non-Genetic Factors Influence CYP2B6 Enzyme Function. Scientific Reports, 12, Article No. 2984. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Wang, P.F., Neiner, A. and Kharasch, E.D. (2019) Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry. Drug Metabolism and Disposition, 47, 1195-1205. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Patel, R., Barker, J. and ElShaer, A. (2020) Pharmaceu-tical Excipients and Drug Metabolism: A Mini-Review. International Journal of Molecular Sciences, 21, Article No. 8224. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Turpeinen, M., Raunio, H. and Pelkonen, O. (2006) The Func-tional Role of CYP2B6 in Human Drug Metabolism: Substrates and Inhibitors in Vitro, in Vivo and in Silico. Current Drug Metabolism, 7, 705-714. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Spatzenegger, M., Liu, H., Wang, Q., et al. (2003) Analysis of Differential Substrate Selectivities of CYP2B6 and CYP2E1 by Site-Directed Mutagenesis and Molecular Modeling. Journal of Pharmacology and Experimental Theraprutics, 304, 477-487. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Kawashima, Y., Hagiwara, M., Inoue, Y., et al. (2002) Evaluation of Dextromethorphan N-Demethylation Activity as a Biomarker for Cytochrome P450 3A Activity in Man. Pharmacology and Toxicology, 90, 82-88. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Al-Jenoobi, F.I., Al-Thukair, A.A., Alam, M.A., et al. (2014) Effect of Garden Cress Seeds Powder and Its Alcoholic Extract on the Metabolic Activity of CYP2D6 and CYP3A4. Evidence-Based Complementary and Alternative Medicine, 2014, Article ID: 634592. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Shaul, C., Blotnick, S., Adar, L., et al. (2022) Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, Is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance. Clinical Pharmacokinetics, 61, 1187-1198. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Rettie, A.E. and Jones, J.P. (2005) Clinical and Toxicological Relevance of CYP2C9: Drug-Drug Interactions and Pharmacogenetics. Annual Review Pharmacology and Toxicology, 45, 477-494. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Daly, A.K., Rettie, A.E., Fowler, D.M., et al. (2018) Pharmacogenomics of CYP2C9: Functional and Clinical Considerations. Journal of Personalized Medicine, 8, 1-31. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Uehara, S., Yoneda, N., Higuchi, Y., et al. (2021) Me-thyl-Hydroxylation and Subsequent Oxidation to Produce Carboxylic Acid Is the Major Metabolic Pathway of Tolbut-amide in Chimeric TK-NOG Mice Transplanted with Human Hepatocytes. Xenobiotica, 51, 582-589. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Rudesheim, S., Selzer, D., Fuhr, U., et al. (2022) Physio-logically-Based Pharmacokinetic Modeling of Dextromethorphan to Investigate Interindividual Variability within CYP2D6 Activity Score Groups. CPT Pharmacometrics Systems Pharmacology, 11, 494-511. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Uehara, S., Ishii, S., Uno, Y., et al. (2017) Regio- and Stereo-Selective Oxidation of a Cardiovascular Drug, Metoprolol, Mediated by Cytochrome P450 2D and 3A Enzymes in Marmoset Liv-ers. Drug Metabolism and Disposition, 45, 896-899. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Cazet, L., Bul-teau, S., Evin, A., et al. (2018) Interaction between CYP2D6 Inhibitor Antidepressants and Codeine: Is This Relevant. Expert Opinion on Drug Metabolism Toxicology, 14, 879-886. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Fernandez-Abascal, J., Ripullone, M., Valeri, A., et al. (2018) β-Naphtoflavone and Ethanol Induce Cytochrome P450 and Protect towards MPP (+) Toxicity in Human Neuroblastoma SH-SY5Y Cells. International Journal of Molecular Sciences, 19, Article No. 3369. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Thorn, H.A., Lundahl, A., Schrickx, J.A., et al. (2011) Drug Metabo-lism of CYP3A4, CYP2C9 and CYP2D6 Substrates in Pigs and Humans. European Journal of Pharmaceutical Scienc-es, 43, 89-98. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Mahli, A., Erwin, T.W. and Hellerbrand, C. (2019) Establishment of a p-Nitrophenol Oxidation-Based Assay for the Analysis of CYP2E1 Activity in Intact Hepatocytes in Vitro. Toxicol-ogy Mechanisms and Methods, 29, 219-223. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Yamamura, Y., Koyama, N. and Umehara, K. (2015) Com-prehensive Kinetic Analysis and Influence of Reaction Components for Chlorzoxazone 6-Hydroxylation in Human Liver Microsomes with CYP Antibodies. Xenobiotica, 45, 353-360. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Hohmann, N., Blank, A., Burhenne, J., et al. (2019) Simulta-neous Phenotyping of CYP2E1 and CYP3A Using Oral Chlorzoxazone and Midazolam Microdoses. Britain Journal of Clinical Pharmacology, 85, 2310-2320. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Pratt-Hyatt, M., Lin, H.L. and Hollenberg, P.F. (2010) Mechanism-Based Inactivation of Human CYP2E1 by Diethyldithocarbamate. Drug Metabolism and Disposition, 38, 2286-2292. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Santes-Palacios, R., Olguin-Reyes, S., Hernandez-Ojeda, S.L., et al. (2020) Differential Inhibition of Naringenin on Human and Rat Cytochrome P450 2E1 Activity. Toxicology in Vitro, 69, Article ID: 105009. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Denisov, I.G., Grinkova, Y.V., Camp, T., et al. (2021) Midazolam as a Probe for Drug-Drug Interactions Mediated by CYP3A4: Homotropic Allosteric Mechanism of Site-Specific Hy-droxylation. Biochemistry-Us, 60, 1670-1681. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Kapetas, A.J., Sorich, M.J., Rodrigues, A.D., et al. (2019) Guidance for Rifampin and Midazolam Dosing Protocols to Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction. AAPS Journal, 21, 78. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Niwa, T., Yasuda, S., Yamamoto, Y., et al. (2021) Contribution of the Human Cytochrome P450 2C Subfamily to the Metabolism of and the Interactions with Endogenous Compounds Including Steroid Hormones. Die Pharmazie, 76, 611-613.
|
|
[50]
|
Kandel, S.E., Han, L.W., Mao, Q.C., et al. (2017) Dig-ging Deeper into CYP3A Testosterone Metabolism: Kinetic, Regioselectivity, and Stereoselectivity Differences between CYP3A4/5 and CYP3A7. Drug Metabolism and Disposition, 45, 1266-1275. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
于敏, 张双庆, 闻镍, 等. 细胞色素P450酶系体外药物代谢研究方法进展[J]. 中国药事, 2013, 27(1): 81-87.
|
|
[52]
|
Liu, Y., Hao, H., Liu, C., et al. (2007) Drugs as CYP3A Probes, Inducers, and Inhibitors. Drug Metabolism Reviews, 39, 699-721. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Stresser, D.M., Broudy, M.I., Ho, T., et al. (2004) Highly Se-lective Inhibition of Human CYP3Aa in Vitro by Azamulin and Evidence That Inhibition Is Irreversible. Drug Metabo-lism and Disposition, 32, 105-112. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Zlabek, V. and Zamaratskaia, G. (2011) Comparison of Three Fluores-cent CYP3A Substrates in Two Vertebrate Models: Pig and Atlantic Salmon. Animal, 6, 633-640. [Google Scholar] [CrossRef]
|
|
[55]
|
Jana, Z. and Meike, M. (2016) Inhibition of in Vitro Metabolism of Testosterone in Human, Dog and Horse Liver Microsomes to Investigate Species Differences. Toxicology in Vitro, 29, 468-478. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Haarhoff, Z.E., Kramer, M.A., Zvyaga, T.A., et al. (2016) Compre-hensive Evaluation of Liver Microsomal Cytochrome P450 3A (CYP3A) Inhibition: Comparison of Cynomolgus Mon-key and Human. Xenobiotica, 47, 470-478. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Uehara, S., Yoneda, N., Higuchi, Y., et al. (2016) Cyto-chrome P450-Dependent Drug Oxidation Activities and Their Expression Levels in Liver Microsomes of Chimeric TK-NOG Mice with Humanized Livers. Drug Metabolism Pharmacokinetics, 44, Article ID: 100454. [Google Scholar] [CrossRef] [PubMed]
|